TOXICOLOGICAL PROFILE FOR ACETONE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service

Agency for Toxic Substances and Disease Registry

May 1994

ACETONE II DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

ACETONE UPDATE STATEMENT

This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles contact ATSDR at:

Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The revised list of the 275 most hazardous substances was published in the Federal Register on October 28, 1992 (57 FR 48801). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); and October 17, 1991 (56 FR 52166).

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicological information and epidemiological evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the <u>Federal Register</u> on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to succinctly characterize the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, that describes in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

Foreword

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

David Satcher, M.D., Ph.D.

Administrator

Agency for Toxic Substances and

Disease Registry

CONTRIBUTORS

CHEMICAL MANAGERS(S)/AUTHOR(S):

Hugh Hansen, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA

Sharon B. Wilbur, M.A. Syracuse Research Corporation, Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

- 1. Green Border Review. Green Border review assures the consistency with ATSDR policy.
- 2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying endpoints.
- 3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
- 4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.

A peer review panel was assembled for acetone. The panel consisted of the following members:

- 1. Dr. Elizabeth Jeffery, Associate Professor of Toxicology, University of Illinois, Urbana, Illinois
- 2. Dr. Peter G. Lacouture, Associate Director, Clinical Research, Purdue Frederick Company, Norwalk, Connecticut
- 3. Dr. John Morris, Associate Professor of Pharmacology and Toxicology, Toxicology Program, School of Pharmacy, University of Connecticut, Storrs, Connecticut.

These experts collectively have knowledge of acetone's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

| FC | REW | ORD | | | V |
|----|-------|-------------|---------|--|-----|
| CC | ONTR | IBUTO | RS | | vii |
| PE | ER R | EVIEW | / | | ix |
| LI | ST OI | FIGU | RES | | χV |
| 1. | PUB | LIC H | EALTH S | STATEMENT | 1 |
| | 1.1 | | | ETONE? | |
| | 1.2 | | | ENS TO ACETONE WHEN IT ENTERS THE ENVIRONMENT? | |
| | 1.3 | | | I BE EXPOSED TO ACETONE? | |
| | 1.4 | | | CETONE ENTER AND LEAVE MY BODY? | |
| | 1.5 | | | CETONE AFFECT MY HEALTH? | |
| | 1.6 | IS TH | ERE A N | MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN | |
| | | EXPO | SED TO | ACETONE? | 8 |
| | 1.7 | WHA | T RECO | MMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO | |
| | | PROT | ECT HU | MAN HEALTH? | 8 |
| | 1.8 | WHE | RE CAN | I GET MORE INFORMATION? | 9 |
| 2. | HEA | ITHE | EFFCTS | | 11 |
| ۷. | 2.1 | | ODUCTI | | 11 |
| | 2.2 | | | | 11 |
| | 2.2 | 2.2.1 | | | 13 |
| | | 2.2.1 | 2.2.1.1 | 1 | 13 |
| | | | 2.2.1.2 | | 13 |
| | | | 2.2.1.3 | Immunological Effects | 29 |
| | | | 2.2.1.4 | Neurological Effects | 29 |
| | | | 2.2.1.5 | Reproductive Effects | 32 |
| | | | 2.2.1.6 | Developmental Effects | 33 |
| | | | 2.2.1.7 | • | 34 |
| | | | 2.2.1.8 | Cancer | 34 |
| | | 2.2.2 | Oral Ex | | 34 |
| | | | 2.2.2.1 | Death | 34 |
| | | | 2.2.2.2 | Systemic Effects | 35 |
| | | | 2.2.2.3 | Immunological Effects | 50 |
| | | | 2.2.2.4 | Neurological Effects | 50 |
| | | | 2.2.2.5 | Reproductive Effects | 52 |
| | | | 2.2.2.6 | Developmental Effects | 52 |
| | | | 2.2.2.7 | Genotoxic Effects | 53 |
| | | | 2.2.2.8 | Cancer | 53 |
| | | 2.2.3 | Dermal | Exposure | 53 |
| | | | 2.2.3.1 | Death | 53 |
| | | | 2.2.3.2 | Systemic Effects | 54 |
| | | | 2.2.3.3 | $\boldsymbol{\mathcal{U}}$ | 60 |
| | | | 2.2.3.4 | Neurological Effects | 60 |

ACETONE xii

| | | | 2.2.3.5 Reproductive Effects |
|----|-----|------------|---|
| | | | 2.2.3.6 Developmental Effects |
| | | | 2.2.3.7 Genotoxic Effects 61 |
| | | | 2.2.3.8 Cancer 61 |
| | 2.3 | TOXI | COKINETICS 62 |
| | | 2.3.1 | Absorption |
| | | | 2.3.1.1 Inhalation Exposure |
| | | | 2.3.1.2 Oral Exposure |
| | | | 2.3.1.3 Dermal Exposure |
| | | 2.3.2 | Distribution |
| | | | 2.3.2.1 Inhalation Exposure |
| | | | 2.3.2.2 Oral Exposure |
| | | | 2.3.2.3 Dermal Exposure |
| | | | 2.3.2.4 Other Routes of Exposure |
| | | 2.3.3 | Metabolism |
| | | 2.3.4 | Excretion |
| | | | 2.3.4.1 Inhalation Exposure |
| | | | 2.3.4.2 Oral Exposure |
| | | | 2.3.4.3 Dermal Exposure |
| | | | 2.3.4.4 Other Routes of Exposure |
| | | 2.3.5 | Mechanism of Action |
| | 2.4 | | VANCE TO PUBLIC HEALTH |
| | 2.5 | | ARKERS OF EXPOSURE AND EFFECT |
| | 2.5 | 2.5.1 | Biomarkers Used to Identify or Quantify Exposure to Acetone |
| | | 2.5.2 | Biomarkers Used to Characterize Effects Caused by Acetone |
| | 2.6 | | RACTIONS WITH OTHER SUBSTANCES |
| | 2.7 | | LATIONS THAT ARE UNUSUALLY SUSCEPTIBLE |
| | 2.8 | | IODS FOR REDUCING TOXIC EFFECTS |
| | 2.0 | 2.8.1 | Reducing Peak Absorption Following Exposure |
| | | 2.8.2 | Reducing Body Burden |
| | | 2.8.3 | Interfering with the Mechanism of Action for Toxic Effects |
| | 2.9 | | UACY OF THE DATABASE |
| | 2.9 | 2.9.1 | |
| | | 2.9.1 | Existing Information on Health Effects of Acetone |
| | | | Identification of Data Needs |
| | | 2.9.3 | On-going Studies |
| 2 | CHE | 'NATO' A T | AND PHYSICAL INFORMATION |
| Э. | | | |
| | 3.1 | | IICAL IDENTITY |
| | 3.2 | PH 13. | ICAL AND CHEMICAL PROPERTIES |
| 4. | DDO | ПІСТІ | ON, IMPORT/EXPORT, USE, AND DISPOSAL |
| 4. | 4.1 | | UCTION |
| | 4.1 | | RT/EXPORT |
| | 4.2 | | |
| | | | |
| | 4.4 | DISLC | OSAL 173 |

ACETONE xiii

| 5. | | ENTIAL FOR HUMAN EXPOSURE | |
|----|--------|--|-------------|
| | 5.1 | OVERVIEW | |
| | 5.2 | RELEASES TO THE ENVIRONMENT | |
| | | 5.2.2 Water | |
| | | 5.2.3 Soil | |
| | 5.3 | ENVIRONMENTAL FATE | |
| | | 5.3.1 Transport and Partitioning | |
| | | 5.3.2 Transformation and Degradation | 184 |
| | | 5.3.2.1 Air | |
| | | 5.3.2.2 Water | |
| | | 5.3.2.3 Sediment and Soil | |
| | 5.4 | LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT | |
| | | 5.4.1 Air | |
| | | 5.4.2 Water | |
| | | 5.4.3 Sediment and Soil | |
| | 5.5 | GENERAL POPULATION AND OCCUPATIONAL EXPOSURE | |
| | 5.6 | POPULATIONS WITH POTENTIALLY HIGH EXPOSURES | |
| | 5.7 | ADEQUACY OF THE DATABASE | |
| | | 5.7.1 Identification of Data Needs | |
| | | 5.7.2 On-going Studies | 196 |
| 6 | 4 NT / | ALYTICAL METHODS | 107 |
| υ. | 6.1 | BIOLOGICAL MATERIALS | |
| | 6.2 | ENVIRONMENTAL SAMPLES | |
| | 6.3 | ADEQUACY OF THE DATABASE | |
| | | 6.3.1 Identification of Data Needs | |
| | | 6.3.2 On-going Studies | 204 |
| 7 | REG | GULATIONS AND ADVISORIES | 205 |
| ٠. | KLO | TOLKITONO INID IID VISORILS | 200 |
| 8. | REF | ERENCES | 209 |
| 9. | GLC | OSSARY | 245 |
| | | | |
| AF | PENI | DICES | |
| | A. 1 | USER'S GUIDE | A- 1 |
| | В | ACRONYMS, ABBREVIATIONS, AND SYMBOLS | B-1 |
| | | | |

| | · | | |
|--|---|--|--|
| | | | |
| | | | |
| | | | |

LIST OF FIGURES

| 2-1 | Levels of Significant Exposure to Acetone - Inhalation | 22 |
|-----|--|-----|
| 2-2 | Levels of Significant Exposure to Acetone - Oral | 42 |
| 2-3 | Proposed Metabolic Pathways for Acetone | 75 |
| 2-4 | Existing Information on Health Effects of Acetone | 147 |
| 5-1 | Frequency of NPL Sites With Acetone Contamination | 176 |

LIST OF TABLES

| 2-1 | Levels of Significant Exposure to Acetone - Inhalation | 14 |
|-----|--|------|
| 2-2 | Levels of Significant Exposure to Acetone - Oral | . 36 |
| 2-3 | Levels of Significant Exposure to Acetone - Dermal | 55 |
| 2-4 | Genotoxicity of Acetone In Vivo | 112 |
| 2-5 | Genotoxicity of Acetone In Vitro | 114 |
| 3-1 | Chemical Identity of Acetone | 166 |
| 3-2 | Physical and Chemical Properties of Acetone | 167 |
| 4-1 | U.S. Manufacturers of Acetone in 1991 | 170 |
| 4-2 | Facilities That Manufacture or Process Acetone | 171 |
| 5-1 | Releases to the Environment from Facilities That Manufacture or Process Acetone | 180 |
| 5-2 | Acetone Levels in the Troposphere and Urban, Rural, and Remote Areas in the United States and Canada | 188 |
| 5-3 | Concentrations of Acetone in Body Fluids and Expired Air of Humans | 192 |
| 6-1 | Analytical Methods for Determining Acetone in Biological Materials | 198 |
| 6-2 | Analytical Methods for Determining Acetone in Environmental Samples | 201 |
| 7-1 | Regulations and Guidelines Applicable to Acetone | 206 |